Recent advances in osteosarcoma

Area of Science:

• Oncology
• Pediatric Oncology
• Cancer Research

Background:

• Osteosarcoma (OS) is a rare but aggressive bone cancer, a leading cause of cancer death in children and adolescents.
• Tumor heterogeneity and low prevalence present significant challenges in developing effective treatments and improving patient survival rates.
• Current therapeutic strategies often involve immune system stimulation or kinase inhibition (e.g., Src, mTOR).

Purpose of the Study:

• To review current clinical trials for osteosarcoma.
• To discuss novel therapeutic targets and the importance of preclinical validation.
• To advocate for enhanced collaboration and individualized treatment approaches for osteosarcoma patients.

Main Methods:

• Review of existing clinical trials for osteosarcoma.
• Discussion of targeted therapies, including tumor-targeted TNFalpha.
• Emphasis on preclinical validation and interdisciplinary cooperation.

Main Results:

• Current trials focus on immunotherapy and kinase inhibitors (Src, mTOR).
• Tumor-targeted TNFalpha shows potential efficacy.
• Preclinical validation is crucial for advancing new therapeutic targets.

Conclusions:

• Improved osteosarcoma patient survival requires intensified exchange between clinicians and basic researchers.
• Individualized treatment strategies, facilitated by interdisciplinary cooperation in Sarcoma Centers, are essential for future success.
• Further research into novel targets and robust preclinical validation is critical for advancing osteosarcoma therapy.